appendix vi statutory and general information

FURTHER INFORMATION ABOUT THE COMPANY

Incorporation

The Company was established as a limited liability company under the laws of the PRC

on October 7, 1998 and was converted into a joint stock company with limited liability on

September 20, 2011.

The Company has established a place of business in Hong Kong at 40th Floor, Dah Sing

Financial Centre, 248 Queen’s Road East, Wanchai, Hong Kong. The Company was registered

as a non-Hong Kong company in Hong Kong under Part 16 of the Companies Ordinance

(Chapter 622 of the Laws of Hong Kong) and the Companies (Non-Hong Kong Companies)

Regulation (Chapter 622J of the Laws of Hong Kong) on [●], 2021, with Mr. Cheng Ching Kit

of 40th Floor, Dah Sing Financial Centre, 248 Queen’s Road East, Wanchai, Hong Kong

appointed as the Hong Kong authorised representative of the Company for acceptance of the

service of process and any notices required to be served on the Company in Hong Kong.

As the Company was incorporated in the PRC, its operations are subject to the relevant

laws and regulations of the PRC. A summary of the relevant aspects of laws and regulations

of the PRC and the Articles of Association is set out in Appendix IV and Appendix V,

respectively.

Changes in the Share Capital of the Company

On December 4, 2019, the registered capital of the Company was decreased from

RMB231,409,962 to RMB231,382,162, the decreased capital of which were repurchased and

canceled by the Company due to resignation of certain employees under the A Share Incentive

Schemes.

On May 18, 2020, the registered capital of the Company was decreased from



Schemes.

On September 9, 2020, the registered capital of the Company was increased from

RMB231,319,762 to RMB232,337,762 due to granting of restricted A Shares under the A Share

Incentive Schemes.

On September 30, 2020, the registered capital of the Company was increased from

RMB232,337,762 to RMB242,516,493 due to a private placing of the Company of the A

Shares.

APPENDIX VI STATUTORY AND GENERAL INFORMATION

– VI-1 –

THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THE INFORMATION MUST BEREAD IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT

On November 30, 2020, the registered capital of the Company was decreased from



Schemes.

On February 8, 2021, the registered capital of the Company was increased from

RMB242,514,693 to RMB242,690,693 due to granting of restricted A Shares under the A Share

Incentive Schemes.

On March 22, 2021, the registered capital of the Company was decreased from



Schemes.

Save as disclosed above, there has been no alteration in the share capital of the Company

within two years immediately preceding the date of this document.

Resolutions Passed by Our Shareholders’ General Meeting in Relation to the[REDACTED]

At the extraordinary general meeting of the Shareholders held on June 16, 2021, the

following resolutions, among other things, were duly passed:

(i) the issue by the Company of H Shares with a nominal value of RMB1.00 each and

such H Shares be [REDACTED] on the Hong Kong Stock Exchange;

(ii) the number of H shares to be issued shall be no more than [REDACTED]% of the

total issued share capital upon the [REDACTED] (before the exercise of the

[REDACTED]), and the grant of the [REDACTED] in respect of no more than

[REDACTED]% of the number of H Shares issued pursuant to the [REDACTED];

(iii) authorization of the Board or its authorized individual to handle all matters relating

to, among other things, the [REDACTED], the issue and [REDACTED] of H

Shares on the Hong Kong Stock Exchange; and

(iv) subject to the completion of the [REDACTED], the conditional adoption of the

revised Articles of Association, which shall become effective on the [REDACTED].


– VI-2 –


Our Subsidiaries

The following table shows the details of our subsidiaries as of the Latest Practicable Date:

No. NameDate ofestablishment

Place ofincorporation Nature of Business

RegisteredCapital

(RMB in10 thousand

unlessotherwiseindicated) Shareholding

1 Asymchem Laboratories(Fuxin)

April 1, 2002 PRC manufacturing, salesand development ofbiotechnologicalproducts andorganic chemicalproducts

331 100%

2 Asymchem Life Science December 30,2005

PRC manufacturing andtoll manufacturingof drugs

7,000 100%

3 Jilin AsymchemLaboratories

August 17,2007

PRC manufacturing, salesand development ofmedicine rawmaterials andrelevant products

29,149 100%

4 Liaoning AsymchemLaboratories Co., Ltd.(遼寧凱萊英醫藥化學有限公司) (“LiaoningAsymchemLaboratories”)

December 2,2013

PRC manufacturing, tollmanufacturing andselling drugs,chemical products

920 100%

5 Tianjin Canal PharmtechCo., Ltd.(天津凱諾醫藥科技發展有限公司) (“Tianjin CanalPharmtech”)

August 10,2017

PRC wholesaling andretailing drugs

4,000 100%

6 Jilin AsymchemPharmaceuticals Co., Ltd.(吉林凱萊英製藥有限公司)

September29, 2017

PRC manufacturing, salesand development ofmedicine rawmaterials andrelevant products

30,000 100%


– VI-3 –




RegisteredCapital

(RMB in10 thousand


7 Shanghai AsymchemBiotechnology Co., Ltd.(上海凱萊英生物技術有限公司) (“ShanghaiAsymchemBiotechnology”)

January 28,2019

PRC manufacturing, salesand development ofbiotechnologicalproducts andorganic chemicalproducts

25,000 100%

8 Asymchem Laboratories(Jilin) Co., Ltd.(凱萊英醫藥化學(吉林)技術有限公司)

May 25, 2020 PRC manufacturing, salesand development ofmedicine rawmaterials andrelevant products

30,000 100%

9 Asymchem Pharmaceuticals(Jiangsu) Co., Ltd.(凱萊英製藥(江蘇)有限公司)

September29, 2020

PRC manufacturing, salesand development ofmedicine rawmaterials

30,000 100%

10 Asymchem Life Science(Jiangsu) Co., Ltd.(凱萊英生命科學技術(江蘇)有限公司)

March 18,2021

PRC exporting, importingdrugs anddevelopment ofmedical research

10,000 100%

11 Asymchem Inc. October 12,2010

United States sales of High-techpharmaceutical rawmaterials andintermediates, geneengineeringoptimized strainsof fermentedpharmaceuticalingredients andbio-enzymaticchemicalpharmaceuticalingredients andpreparationproducts

N/A(1) 100%

12 Asymchem Limited February 13,2017

UnitedKingdom

sales and import andexport trade

C1 100%


– VI-4 –




RegisteredCapital

(RMB in10 thousand


13 Asymchem BostonCorporation

December 14,2020

United States pharmaceuticalresearch anddevelopment,intermediatewholesaledistributor ofactivepharmaceuticalingredients

N/A(2) 100%

14 Tianjin AsymchemPharmaceutical Analysis,Testing and EvaluationCo., Ltd. (天津凱萊英藥物分析檢測評價有限公司)

July 29, 2013 PRC analysis and detectionof biomedicine andchemical industryproducts

100 100%

15 GoalGen November28, 2007

PRC manufacturing, salesand development ofbiotechnologicalproducts andorganic chemicalproducts

1,000 100%

16 Asymchem Taixin ClinicalStudy Co., Ltd.(凱萊泰欣臨床研究(天津)有限公司)

March 6,2020

PRC exporting, importingproducts, medicalresearch and trialsdevelopment

1,000 51%(3)

17 Tianjin BaiboshengPharmtech Co., Ltd.(天津百博生醫藥科技有限公司)

November21, 2018

PRC development ofbiomedicaltechnology,medical research,research anddevelopment ofdrugs

500 100%


– VI-5 –




RegisteredCapital

(RMB in10 thousand


18 Shanghai XinzhuoPharmaceutical Researchand Development Co.,Ltd. (上海新卓醫藥研究開發有限公司)

December 5,2019

PRC research anddevelopment ofdrugs, developmentof biomedicaltechnology andchemicaltechnology

1,000 100%

19 Tianjin Yinuo QinkangMedical Technology Co.,Ltd. (天津醫諾勤康醫學科技有限公司)

July 29, 2020 PRC medical research andtrials development,big data service,sales of medicaldevices

200 100%

20 Tianjin AsymchemPharmaceuticals Co., Ltd.(天津凱萊英製藥有限公司) (“Tianjin AsymchemPharmaceuticals”)

July 19, 2010 PRC manufacturing ofdrugs, medicalproducts,pharmaceuticalequipment, medicalresearch and trialsdevelopment

22,483 100%(4)

21 Shanghai Nuoxin YingkeInformation TechnologyCo., Ltd. (上海諾信英科信息科技有限公司)

June 15, 2021 PRC Technical service,technicaldevelopment andtechnicalconsultation

500 100%

Notes:

1. Asymchem Inc. is authorised to issue a total of 20,000,000 shares of Common Stock without par value.

2. Asymchem Boston Corporation is authorised to issue a total of 275,000 shares of a single class without parvalue.

3. As of the Latest Practicable Date, the other 49% equity interest in Asymchem Taixin Clinical Study Co., Ltd.(凱萊泰欣臨床研究(天津)有限公司) was held by Teda International Cardiovascular Hospital Co., Ltd. (泰達國際心血管病醫院有限公司), an independent third party of the Company.

4. The Company holds 97.01% direct interest and 2.99% indirect interest through Asymchem Life Science, awholly owned subsidiary of the Company.

Save as disclosed above, so far as is known to any Director or chief executive of the

Company, as at the Latest Practicable Date, no person is directly or indirectly interested in 10%

or more of the issued voting shares of the subsidiary of the Company.


– VI-6 –


The following subsidiaries of the Company were incorporated within two yearsimmediately preceding the date of this document:

Name of SubsidiaryPlace ofIncorporation

Date ofIncorporation

Asymchem Laboratories (Jilin) Co., Ltd.(凱萊英醫藥化學(吉林)技術有限公司)

PRC May 25, 2020

Asymchem Pharmaceuticals (Jiangsu) Co.,Ltd. (凱萊英製藥(江蘇)有限公司)

PRC September 29, 2020

Asymchem Life Science (Jiangsu) Co., Ltd.(凱萊英生命科學技術(江蘇)有限公司)

PRC March 18, 2021

Asymchem Boston Corporation United States December 14, 2020

Asymchem Taixin Clinical Study Co., Ltd.(凱萊泰欣臨床研究(天津)有限公司)

PRC March 6, 2020

Shanghai Xinzhuo Pharmaceutical Researchand Development Co., Ltd.(上海新卓醫藥研究開發有限公司)

PRC December 5, 2019

Tianjin Yinuo Qinkang Medical TechnologyCo., Ltd. (天津醫諾勤康醫學科技有限公司)

PRC July 29, 2020

Shanghai Nuoxin Yingke InformationTechnology Co., Ltd.(上海諾信英科信息科技有限公司)

PRC June 15, 2021

Details of the changes in the share capital of the Company’s subsidiaries during the twoyears immediately preceding the date of this document are set out below:

Save for the registered capital of Jilin Asymchem Laboratories was increased fromRMB87.6 million to RMB291.49 million on April 15, 2020, there has been no alteration in theshare capital of the subsidiaries of the Company within two years immediately preceding thedate of this document.


– VI-7 –


FURTHER INFORMATION ABOUT THE BUSINESS

Summary of Material Contracts

The Group has entered into the following contracts (not being contracts entered into in theordinary course of business) within the two years immediately preceding the date of thisdocument that are or may be material:

(a) the [REDACTED]; and

(b) [●].

Intellectual Property

As at the Latest Practicable Date, the following intellectual property rights are materialto the Group’s business:

Trademarks

As at the Latest Practicable Date, the Group had registered the following trademarks

which are material to its business:

No. Trademark ClassRegisteredOwner

Place ofRegistration

RegistrationNumber Expiry Date

1. ASYMCHEM 1 The Company PRC 9027665 January 21,

20222. 1 The Company PRC 9027705 January 21,

20223. 凱萊英 1 The Company PRC 9027772 January 21,

20224. ASYMCHEM 40 The Company PRC 9025464 January 14,

20225. 40 The Company PRC 9025477 January 14,

20226. 凱萊英 40 The Company PRC 9027802 January 21,

20227. ASYMCHEM 42 The Company PRC 9027846 July 21, 20228. 42 The Company PRC 9027900 July 21, 2022

9. 凱萊英 42 The Company PRC 9027963 July 14, 202210. ASYMCHEM 1, 40, 42 Asymchem Inc. United States 3523597 October 28,

202811. 1, 40, 42 Asymchem Inc. United States 3523598 October 28,

2028


– VI-8 –


No. Trademark ClassRegisteredOwner

Place ofRegistration

RegistrationNumber Expiry Date

12. 1, 5, 40,

42

The Company Hong Kong 304621752 August 3,

202813. 1, 5, 40,

42


202814. 1, 5, 40,

42


202815. 42 GoalGen PRC 23177294 March 7,



202818. 42 GoalGen PRC 22045853 January 14,




2028

Domain Names

As at the Latest Practicable Date, the Group had registered the following domain names

which are material to its business:

No. Domain Name Registered Owner Expiry Date

1. asymchem.com.cn the Company July 9, 2028


– VI-9 –


Patents

As at the Latest Practicable Date, the Group had registered the following patents which

are material to its business:

No Patent Name Type Patent HolderJurisdiction ofRegistration Patent Number

Date ofApplication

Duration ofPatent Right(1)(2)

1. ContinuousOzonization Reactor

UtilityModel

The Company/Asymchem LifeScience/TianjinAsymchemPharmaceuticals/AsymchemLaboratories(Fuxin)/JilinAsymchemLaboratories

PRC ZL2012201284577 March 30,2012

10 years

2. A Reactor forContinuously andSafely ProducingDiazomethane on aLarge Scale and ItsWorking Methods

Invention The Company PRC ZL2010102076153 June 24, 2010 20 years

3. A Method to Prepare7-bromo-1-heptene

Invention The Company/Asymchem LifeScience/TianjinAsymchemPharmaceuticals/AsymchemLaboratories(Fuxin)/JilinAsymchemLaboratories

PRC ZL2012101647240 May 24, 2012 20 years

4. A Method to PrepareSulfobutyl ether-�-cyclodextrin


PRC ZL2014100121627 January 10,2014

20 years


– VI-10 –



Date ofApplication


5. Synthetic Method ofToremifene


PRC ZL2014104159002 August 21,2014

20 years

6. Carboxyl Polymer, itsPreparation Methodand Usage andPreparation Methodof Intermediates ofCarbapenemsAntibiotics


PRC ZL2014104597083 September 10,2014

20 years

7. The Reactor and theReaction SystemThereof (PortableContinuous Low-temperatureReaction Unit on aLarge Scale

UtilityModel

The Company/Asymchem LifeScience/TianjinAsymchemPharmaceuticals/AsymchemLaboratories(Fuxin)/JilinAsymchemLaboratories

PRC ZL2016203903137 April 29, 2016 10 years

8. Dicarbonyl Reductase,its Encoding Geneand Applications


PRC ZL201410188168X May 6, 2014 20 years


– VI-11 –



Date ofApplication


9. Dicarbonyl Reductase,its Encoding Geneand Applications


PRC ZL2014101891874 May 6, 2014 20 years

10. Transaminase and itsApplication


PRC ZL2014106062529 October 31,2014

20 years

11. Dicarbonyl ReductaseMutants and itsApplication


PRC ZL2017110409403 May 9, 2014 20 years



PRC ZL2014108025492 December 19,2014

20 years


– VI-12 –



Date ofApplication


13. Carboxyl Polymer, itsPreparation Methodand Usage,Supported Catalystand PreparationMethod ofIntermediates ofCarbapenemsAntibiotics


Japan 6227147 September 10,2014

20 years

14. A Synthetic Device ofOrganicPhosphonates

UtilityModel

Asymchem LifeScience

PRC ZL2017206517542 June 5, 2017 10 years

15. ContinuousPhotochemicalReactor and itsSystem

UtilityModel

AsymchemLaboratories(Fuxin)

PRC ZL2017209732625 August 4, 2017 10 years

16. Carboxyl Polymer, itsPreparation Methodand Usage andCarbene InsertionReaction Catalyzedby SupportedCatalyst


Korea 10-1851476 September 10,2014

20 years



Japan 6367944 October 31,2014

20 years

18. Low-temperature Full-continuous ReactionSystem

UtilityModel

Jilin AsymchemLaboratories

PRC ZL2018200479359 January 11,2018

10 years


– VI-13 –



Date ofApplication


19. AlcoholDehydrogenaseMutants and itsApplication


PRC ZL201410814234X December 23,2014

20 years



Korea 10-1910259 October 31,2014

20 years

21. ContinuousReplacementReaction Equipmentof Metal-brominatedAromatics andContinuousPreparation Systemof AromaticAldehyde

UtilityModel

AsymchemLaboratories(Fuxin)

PRC ZL2018201587859 January 30,2018

10 years



United States US 10,131,883 B2 August 4, 2014 20 years


– VI-14 –



Date ofApplication




United States US 10,131,962 BS October 31,2014

20 years



Japan 6473175 August 4, 2014 20 years

25. A Method to PrepareSulfobutyl ether-�-cyclodextrin


United States US 10,246,524 B2 October 14,2014

20 years

26. Continuous Unit forPreparingBenzaldehydeIntermediates

UtilityModel


PRC ZL2018214309230 August 31,2018

10 years



Europe EP 3075847 B1 October 31,2014

20 years


– VI-15 –



Date ofApplication


28. A Method to PrepareHydrocarbonylPhosphonates

Invention Asymchem LifeScience

PRC ZL201710321770X May 9, 2017 20 years



Europe EP 3141601 B1 August 4, 2014 20 years

30. MonooxygenaseMutants, itsPreparation Methodand Application

Invention The Company PRC ZL2018101236560 February 7,2018

20 years



United States US 10,399,071 B2 September 10,2014

20 years



Europe EP 3075751 B1 September 10,2014

20 years

33. ContinuousPhotochemicalReactor and itsSystem

UtilityModel

The Company PRC ZL2019203256465 March 14,2019

10 years


– VI-16 –



Date ofApplication


34. ContinuousElectrochemicalReactor and AMethod ofContinuousOxidation ofThioetherSubstrates toSulfone

Invention The Company PRC ZL2017106680337 August 7, 2017 20 years

35. Electrolyzer andElectrolytic System

UtilityModel

The Company PRC ZL201920814583X May 31, 2019 10 years

36. Preparation Method ofChiral �-aminoAcids


PRC ZL2016105393449 July 8, 2016 20 years

37. EtelcalcetideIntermediates and ASynthetic Methodof Etelcalcetide

Invention The Company PRC ZL201911217130X December 3,2019

20 years


Invention The Company/Asymchem LifeScience/TianjinAsymchemPharmaceuticals/AsymchemLaboratories(Fuxin)/JilinAsymchemLaboratories/ShanghaiAsymchemLaboratories

PRC ZL2017110409403 May 9, 2014 20 years

39. Continuous Synthesisand PurificationUnit and itsContinuousReaction SystemThereof

UtilityModel

Jilin AsymchemLaboratories

PRC ZL201921262311X August 6, 2019 10 years


– VI-17 –



Date ofApplication


40. Continuous SyntheticMethod of 2-Chloropyrimidine-4- formic AcidCompounds

Invention Tianjin AsymchemPharmaceuticals

PRC ZL2019111620405 November 25,2019

20 years

41. Synthetic Method ofChiral Fluorine-containing AmineCompounds


20 years

42. Interlocking LinkageCabinet

UtilityModel


PRC ZL2019213642688 August 21,2019

10 years

43. Synthetic Method,Kits andApplications ofD-heterocyclicAmino Acid

Invention The Company PRC ZL2018100647715 January 23,2018

20 years

44. Transaminase Mutantsand its Application

Invention The Company PRC ZL2020103530698 April 29, 2020 20 years

45. Immobilized Enzyme,its PreparationMethod andApplication





PRC ZL2018101125981 February 5,2018

20 years

47. Synthetic Method ofN-Boc-Dolaproineand Boc-DapDCHA


PRC ZL2020104871280 June 2, 2020 20 years

48. Continuous Post-processing Unit ofCarbapenemsCompounds

UtilityModel

The Company PRC ZL2019217282319 October 15,2019

10 years

49. KetoreductaseMutants and itsApplication


PRC ZL2020105100497 June 8, 2020 20 years


– VI-18 –



Date ofApplication


50. A Method to PrepareMultiple-chiralCenter AmineCompounds


PRC ZL2017109368883 October 10,2017

20 years

51. L-amino Acid LigaseSlal, its PreparationMethod andApplication


PRC ZL2020105206561 June 10, 2020 20 years

52. A Method to PrepareMultiple-chiralCenter AlcoholicCompounds

Invention Jilin AsymchemLaboratories

PRC ZL2017109361742 October 10,2017

20 years

53. KetoreductaseMutants and itsApplication


PRC ZL2018100607949 January 22,2018

20 years

54. Continuous SyntheticMethod ofRufinamide

Invention The Company PRC ZL2018111788420 October 10,2018

20 years

55. Synthetic Method ofSulopenem SideChain


PRC ZL2019100745708 January 25,2019

20 years


Invention The Company/Asymchem LifeScience/TianjinAsymchemPharmaeuticals/AsymchemLaboratories(Fuxin)/JilinAsymchemLaboratories

Korea 10-2176054 December 9,2016

20 years

57. PhotochemicalContinuous Reactorand PhotochemicalContinuousReaction System

UtilityModel

LiaoningAsymchemLaboratories

PRC ZL2020204283706 March 27,2020

10 years

58. Grignard ReagentContinuousPreparation Unitand System

UtilityModel




– VI-19 –



Date ofApplication


59. Synthetic Method ofCyclopropaneCompounds


PRC ZL2020108601168 August 25,2020

20 years

60. Preparation Method ofEnzyme Catalystfor Chiral Alcohol


PRC ZL2016108876408 October 11,2016

20 years

61. Preparation Method ofEnzyme Catalystfor Chiral Alcohol


PRC ZL2016109357776 November 1,2016

20 years


Invention The Company/Asymchem LifeScience/TianjinAsymchemPharmaceuticals/AsymchemLaboratories(Fuxin)

India 356941 August 4, 2014 20 years

63. Synthetic Method ofLiquid Phase forEtelcalcetide


PRC ZL2020110343126 September 27,2020

20 years



PRC ZL2017110811016 November 6,2017

20 years


– VI-20 –



Date ofApplication


65. Amino AcidDehydrogenaseMutants and itsApplication


PRC ZL2018109423851 August 17,2018

20 years

66. MonooxygenaseMutants, itsPreparation Methodand Application


20 years

67. Cytochrome P450Enzyme Mutantsand its Application


PRC ZL2021100394588 January 13,2021

20 years

68. Amino AcidHehydrogenaseMutants and itsApplication


PRC ZL2021100785149 January 21,2021

20 years

69. Lipase Mutants andits Application


PRC ZL2021100596946 January 18,2021

20 years

70. Proline Hydroxylaseand its Application


Japan 6870102 November 4,2016

20 years

71. A Method and Systemof RemovingBacteriophagesfrom CompressedAir in FermentationProcess

Invention The Company PRC ZL2017107997999 September 7,2017

20 years

72. Synthetic Method of�-Amino AcidIntermediate

Invention The Company PRC ZL201810670845X June 26, 2018 20 years

73. KetoreductaseMutants andProduction Methodof Chiral Alcohol

Invention The Company PRC ZL2019105118958 June 13, 2019 20 years


– VI-21 –



Date ofApplication


74. PVA MembraneImmobilizedEnzyme and itsPreparation Method


PRC ZL2020106834765 July 16, 2020 20 years


Invention The Company PRC ZL2019110334815 October 28,2019

20 years

76. Esterase Mutants andits Application


PRC ZL2021101070533 January 27,2021

20 years

77. Enzyme-catalyzedDouble-MichaelContinuousAddition Method


PRC ZL202011479821X December 16,2020

20 years

78. Modified KetoneReductase Mutantsand its PreparationMethod andApplication


PRC ZL2017114219658 December 25,2017

20 years

Notes:

1. According to the PRC laws, the duration of a patent right for inventions shall be 20 years and the duration ofa patent right for utility models shall be 10 years, both commencing from the date of application.

2. The duration of the overseas patent rights owned by the Company and its subsidiaries is 20 years, commencingfrom the date of application.


– VI-22 –


As at the Latest Practicable Date, the Group had applied for registration the following

patents which are material to its business:

No Patent Name Type ApplicantJurisdiction ofRegistration

ApplicationNumber

Date ofApplication

1. Proline Hydroxylase and

its Application

Invention The

Company/Asymchem

Life

Science/Tianjin

Asymchem

Pharmaceuticals/Asymchem

Laboratories

(Fuxin)/Jilin

Asymchem

Laboratories

PRC 201610971207.2 November 4,

2016

2. Monooxygenase Mutants

and its Application

Invention The Company PRC 201811307573.3 November 5,

2018

3. Continuous

Photochemical

Reaction Unit and its

System

Invention The Company PRC 201910195168.5 March 14,

2019

4. Continuous synthesis

method of 1,1’-

Bicyclo[1.1.1]

Pentane-1,3-3-

Pentanone

Invention Jilin Asymchem

Laboratories

PRC 201910502689.0 June 11, 2019

5. Continuous synthesis

method of Propellane

compound


Laboratories

PRC 201910527363.3 June 18, 2019

6. Immobilized Enzyme, its

Preparation Method

and Application


Laboratories

PRC 201911360761.7 December 25,

2019

7. Immobilized Enzyme, its

Preparation Method

and Application


Laboratories

PRC 202010038661.9 January 14,

2020


– VI-23 –


No Patent Name Type ApplicantJurisdiction ofRegistration

ApplicationNumber

Date ofApplication

8. PEI Immobilized

Enzyme, its

Preparation Method

and Application

Invention Asymchem Life

Science

PRC 202010664338.2 July 10, 2020

9. Reaction module and its

reactor

Invention Asymchem Life

Science

PRC 202011027481.7 September 25,

2020

10. Preparation device of

Grignard reagent and

preparation system of

Grignard reagent

Utility

Model

The Company PRC 202120354981.5 February 8,

2021

11. A photocatalytic method

for continuous

bromination

Invention The Company PRC 202110226837.8 March 2, 2021

12. Transaminase Mutants

and its Application

Invention The Company PRC 202110451381.5 April 26, 2021

13. Synthetic Method of

chiral amine

Invention The Company PRC 202110451383.4 April 26, 2021

14. Preparation method of

polypeptide

Invention The Company PRC 202110554938.8 May 21, 2021


– VI-24 –


Software copyrights

As of the Latest Practicable Date, the Group had registered the following softwarecopyrights which are material to its business:

No Software Name RegistrantRegistrationNumber

Date ofRegistration

1. Automatic thermostaticheating system V1.0(全自動恒溫加熱系統V1.0)


2018SR685321 August 27,2018

2. Pressure, temperature andliquid level detectionsystem V1.0 (壓力溫度液位檢測系統V1.0)


2018SR691071 August 29,2018

3. Clinical drug preparationprocedure supervisionsystem V1.0 (臨床藥物制備流程監管系統V1.0)

Tianjin CanalPharmtech

2021SR0496782 April 6, 2021

4. Clinical drug preparationquality testing systemV1.0 (臨床藥物制備質量檢測系統V1.0)


2021SR0495544 April 6, 2021

5. Clinical drug developmentinformation managementplatform V1.0 (臨床藥物研發信息化管理平台V1.0)


2021SR0494381 April 6, 2021

6. Clinical drug developmenttechnology applicationmanagement systemV1.0 (臨床藥物研發技術應用管理系統V1.0)


2021SR0494533 April 6, 2021

7. Clinical drug developmentprogress managementsystem V1.0 (臨床藥物研發進度管理系統V1.0)


2021SR0500305 April 7, 2021


– VI-25 –


DISCLOSURE OF INTERESTS

Disclosure of Interests of Directors, Supervisors and Chief Executive of the Company

Immediately following the completion of the [REDACTED] (assuming that the

[REDACTED] is not exercised and no additional restricted A Shares are granted under the A

Share Incentive Schemes), the interests and/or short positions (as applicable) of the Directors,

Supervisors and the chief executive of the Company in the Shares, underlying Shares and

debentures of the Company and any interests and/or short positions (as applicable) in shares,

underlying Shares or debentures of any of the Company’s associated corporations (within the

meaning of Part XV of the SFO) which (1) will have to be notified to the Company and the

Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including

interests and/or short positions (as applicable) which they are taken or deemed to have under

such provisions of the SFO), (2) will be required, pursuant to Section 352 of the SFO, to be

entered in the register referred to therein or (3) will be required, pursuant to the Model Code

for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the

Listing Rules, to be notified to the Company and the Hong Kong Stock Exchange, in each case

once the Shares are [REDACTED] on the Hong Kong Stock Exchange, will be as follows:

Interests/Short Positions in the Shares

Name ofShareholder Nature of Interest

Class ofShares

Number ofShares Held

or Interested

ApproximatePercentage ofShareholding

in the RelevantClass of Shares

ApproximatePercentage ofShareholding

in the TotalIssued Share

Capital

(%) (%)

Dr. Hao Hong Beneficial owner A Shares 10,191,928 4.20 [REDACTED]Interest held by

controlled

corporations(1)

A Shares 88,510,520 36.48 [REDACTED]

Mr. Zhang Da Beneficial owner A Shares 72,000 0.03 [REDACTED]Beneficial owner(2) A Shares 108,000 0.05 [REDACTED]

Notes:

1. As of the Latest Practicable Date, Dr. Hao Hong directly held 71.19% equity interest in ALAB. Therefore, Dr.Hao Hong was deemed to be interested in the Shares held by ALAB.

2. Interests in Restricted A Shares granted pursuant to A Share Incentive Schemes.


– VI-26 –


Long Position in Shares of Associated Corporations

Name of Directoror Chief Executive

Name ofAssociatedCorporations

Number ofShares Nature of Interest

ApproximatePercentage

(%)

Dr. Hao Hong ALAB 22,320,000 Beneficial owner 71.19Dr. Ye Song ALAB 6,120,000 Beneficial owner 19.52

Save as disclosed above, none of the Directors, Supervisors or the chief executive of the

Company will, immediately following the completion of the [REDACTED], have an interest

and/or short position (as applicable) in the Shares, underlying Shares or debentures of the

Company or any interests and/or short positions (as applicable) in the shares, underlying

Shares or debentures of the Company’s associated corporations (within the meaning of Part XV

of the SFO) which (i) will have to be notified to the Company and the Hong Kong Stock

Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short

positions which they are taken or deemed to have under such provisions of the SFO), (ii) will

be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein

or (iii) will be required, pursuant to the Model Code for Securities Transactions by Directors

of Listed Issuers as set out in Appendix 10 to the Listing Rules, to be notified to the Company

and the Hong Kong Stock Exchange, in each case once the Shares are [REDACTED] on the

Hong Kong Stock Exchange.

Disclosure of Interests of Substantial Shareholders

For information on the persons who will, immediately following the completion of the

[REDACTED], have interests or short positions in our Shares or underlying Shares which

would be required to be disclosed to us and the Hong Kong Stock Exchange under the

provisions of Divisions 2 and 3 of Part XV of the SFO, or who will directly or indirectly, be

interested in 10% or more of the nominal value of any class of share capital carrying the rights

to vote in all circumstances at general meetings of the Company or of any member of the

Group, see “Substantial Shareholders.”

FURTHER INFORMATION ABOUT DIRECTORS AND SUPERVISORS

Particulars of the Service Contracts

Pursuant to Rules 19A.54 and 19A.55 of the Hong Kong Listing Rules, we will enter into

a contract with each of our Directors and Supervisors in respect of, among other things (i)

compliance of relevant laws and regulations, (ii) observance of the Articles of Association, and

(iii) provisions on arbitration.


– VI-27 –


Save as disclosed above, none of the Directors or Supervisors has entered into any servicecontracts as a director or supervisor with any member of the Group (excluding contractsexpiring or determinable by the employer within one year without payment of compensation(other than statutory compensation)).

Remuneration of Directors and Supervisors

For details of the remuneration of Directors and Supervisors, see “Directors, Supervisorsand Senior Management – Remuneration of the Directors, Supervisors and SeniorManagement” and note 8 in “Appendix I Accountant’s Report.”

Agency Fees or Commissions Received

The [REDACTED] will receive an [REDACTED] commission in connection with the[REDACTED], as detailed in “[REDACTED] – Commissions and Expenses.” Save inconnection with the [REDACTED], no commissions, discounts, brokerages or other specialterms have been granted by the Group to any person (including the Directors, promoters andexperts referred to in “Other Information – Qualifications and Consents of Experts” below) inconnection with the issue or sale of any capital or security of the Company or any member ofthe Group within the two years immediately preceding the date of this document.

Save for the underwriting commission paid to the underwriters in relation to the issuanceof the non-public offering of 10,178,731 A Shares in September 2020 as disclosed in “Historyand Development – Establishment and Development of the Company – 9. Non-public offeringin September 2020”, within the two years immediately preceding the date of this document, nocommission has been paid or is payable for subscription, agreeing to subscribe, procuringsubscription or agreeing to procure subscription for any share in or debentures of the Company.

Personal Guarantees

The Directors have not provided personal guarantees in favour of lenders in connectionwith banking facilities granted to the Group.

Disclaimers

(a) Save as disclosed in the section headed “History and Development,” none of theDirectors, Supervisors nor any of the experts referred to in “Other Information –Qualifications and Consents of Experts” below has any direct or indirect interest inthe promotion of, or in any assets which have been, within the two yearsimmediately preceding the date of this document, acquired or disposed of by, orleased to, any member of the Group, or are proposed to be acquired or disposed ofby, or leased to, any member of the Group.

(b) Save in connection with the [REDACTED], none of the Directors, Supervisors norany of the experts referred to in “Other Information – Qualifications and Consentsof Experts” below, is materially interested in any contract or arrangement subsistingat the date of this document which is significant in relation to the business of theGroup.


– VI-28 –


(c) Neither the Controlling Shareholders nor the Directors are interested in any business

apart from the Group’s business which competes or is likely to compete, directly or

indirectly, with the business of the Group.

(d) No cash, securities or other benefit has been paid, allotted or given within the two

years preceding the date of this document to any promoter of the Company nor is

any such cash, securities or benefit intended to be paid, allotted or given on the basis

of the [REDACTED] or related transactions as mentioned.

(e) So far as is known to the Directors, none of the Directors or their associates or any

Shareholders who are expected to be interested in 5% or more of the issued share

capital of the Company has any interest in the five largest customers or the five

largest suppliers of the Group.

A SHARE INCENTIVE SCHEMES

Pursuant to Administrative Measures for the Equity Incentives of Listed Companies (《上市公司股權激勵管理辦法》) issued by the CSRC, as amended and supplemented from time to

time, the Company may adopt various equity incentive schemes at the same time provided that

the aggregate number of A Shares involved in equity incentive schemes within any validity

period shall not exceed 10% of the Company’s total share capital.

The 2016 Share Option and Restricted A Share Incentive Scheme, the 2018 Restricted A

Share Incentive Scheme, the 2019 Restricted A Share Incentive Scheme and the 2020

Restricted A Share Incentive Scheme (collectively, the “A Share Incentive Schemes”) were

adopted and approved by the Shareholders’ meetings held on January 16, 2017, July 12, 2018,

April 12, 2019, July 9, 2020, respectively. The options granted under the 2016 Share Option

and Restricted A Share Incentive Scheme have all been canceled as at the Latest Practicable

Date. As such, the terms of the A Share Incentive Schemes are not subject to the provisions of

Chapter 17 of the Listing Rules as they do not involve any grant of options by our Company

to subscribe for new Shares after the [REDACTED].

Terms of each of the A Share Incentive Schemes

The terms of each of the A Share Incentive Schemes are substantially similar and are

summarized below.

(a) Purpose

The purpose of the A Share Incentive Schemes is to establish the long-term incentive

mechanism of the Company, attract and retain talents, mobilize the enthusiasm of the directors,

senior management and key technical employees of the Company, foster shared interests

among the shareholders, the Company and operators, thereby promoting sustained, long-term

and healthy growth of the Company.


– VI-29 –


(b) Types of Awards

The A Share Incentive Schemes provides for awards of options (only under 2016 Share

Option and Restricted A Share Incentive Scheme) and restricted A Shares (the “Awards”).

(c) Administration

The Shareholders’ meeting is the highest authority of the A Share Incentive Schemes. The

Board is the managing authority of the A Share Incentive Schemes. The board of Supervisors

and independent non-executive Directors are the supervising authorities of the A Share

Incentive Schemes.

(d) Scope of Participants

The Directors, senior or mid-level management and key technical employees of the

Company (excluding independent non-executive Directors, Supervisors, Shareholders that hold

more than 5% of the Company’s shares and the Controlling Shareholders and their spouses,

parents, and children) (the “Participants”).

(e) Source of Shares

The Shares underlying the A Share Incentive Schemes shall be ordinary A Shares.

(f) Maximum Number of Shares

The maximum number of shares involved with the Awards to be granted to an eligible

employee under all effective A Share Incentive Schemes shall not exceed 1% of the total

outstanding share capital of the Company. The total number of shares involved with all

effective A Share Incentive Schemes shall not exceed 10% of the total outstanding share capital

of the Company.

(g) Validity Period of the A Share Incentive Schemes

Subject to the termination provisions under the A Share Incentive Schemes, the A Share

Incentive Schemes shall be valid and effective commencing on the date that the Awards are

granted (the “Initial Grant”) to when such Awards are no longer under any lock-ups, fully

exercised or cancelled. The term of validity underlying the A Share Incentive Schemes of 2016,

2018, 2020 shall not exceed 60 months. The term of validity underlying the 2019 Restricted

A Share Incentive Scheme shall not exceed 48 months.


– VI-30 –


(h) Date of Grant

The date on which the Awards are granted shall be determined by the Board, subject toapproval of the A Share Incentive Schemes by the shareholders’ meeting, which shall be atrading day. The Awards shall be granted, registered and announced within 60 days after theapproval of the A Share Incentive Schemes by the shareholders’ meeting. Otherwise, the AShare Incentive Schemes shall be terminated, and the Awards thereunder that have not beengranted shall become invalid.

(i) Lock-up Period

The lock-up periods for the Awards underlying the A Share Incentive Schemes are 12months, 24 months and 36 months, respectively, commencing from the date the Awards wereregistered (the “Registration Date”). During the lock-up period, the Awards shall not betransferred, used as guarantee or repayment of debt.

The unlocking periods (each, an “Unlocking Period”) in relation to the Restricted AShares granted under the Initial Grant are as follows:

Unlocking PeriodProportion of

unlocking

First Unlocking Period From the first trading day after 12months from the RegistrationDate to the last trading daywithin 24 months from theRegistration Date

40%

Second Unlocking Period From the first trading day after 24months from the RegistrationDate to the last trading daywithin 36 months from theRegistration Date

30%

Third Unlocking Period From the first trading day after 36months from the RegistrationDate to the last trading daywithin 48 months from theRegistration Date

30%

(j) Grant and Exercise of Awards

On and subject to certain terms of the A Share Incentive Schemes, Awards can be grantedto or exercised by any eligible employee, i.e., linking the grant and exercise of the Awards tothe attainment or performance of milestones by the Company and the grantee. If theperformance of the Company, the relevant grantee and other conditions are not fulfilled in thestipulated period, the Awards shall be repurchased or cancelled by the Company.


– VI-31 –


(k) Amendment or Termination of the A Share Incentive Schemes

Any amendment or termination of the A Share Incentive Schemes shall be submitted to

the Board and shareholders for consideration. The independent Directors and Supervisory

Committee shall express their relevant views and the Company’s legal adviser shall provide

professional advice to the Board whether such adjustment is fair and reasonable and in

compliance with the A Share Incentive Schemes and the relevant laws and regulations. Any

amendment that results in early exercise or unlocking or lowers the exercise price or grant price

is prohibited.

Restricted A Shares Granted

The options granted under the 2016 Share Option and Restricted A Share Incentive

Scheme have all been canceled as at the Latest Practicable Date. As of the Latest Practicable

Date, a total of 1,688,295 restricted A Shares were granted to 262 eligible Participants under

A Share Incentive Schemes other than certain restricted A Shares repurchased and canceled by

the Company due to resignation of certain Participants. The following table set forth the

restricted A Shares held by relevant Participants under the A Share Incentive Schemes as of the

Latest Practicable Date:

Name Position

Number ofrestricted A

Shares grantedup to the Latest

PracticableDate

Percentageto the totalnumber of

Shares in issueas of the Latest

PracticableDate

Percentage to the totalnumber of Shares in

issue immediately afterthe [REDACTED]

(assuming that the[REDACTED] is not

exercised and noadditional restricted A

Shares are grantedunder the A Share

Incentive Schemes)

(%) (%)

DirectorZhang Da Executive Director,

Deputy General

Manager and Chief

Financial Officer

108,000 0.05 [REDACTED]

Senior managementXiao Yi Deputy General

Manager

180,000 0.07 [REDACTED]

Jiang Yingwei Deputy General

Manager

180,000 0.07 [REDACTED]


– VI-32 –


Name Position

Number ofrestricted A

Shares grantedup to the Latest

PracticableDate

Percentageto the totalnumber of

Shares in issueas of the Latest

PracticableDate

Percentage to the totalnumber of Shares in

issue immediately afterthe [REDACTED]

(assuming that the[REDACTED] is not

exercised and noadditional restricted A

Shares are grantedunder the A Share

Incentive Schemes)

(%) (%)

Members of senior or mid-levelmanagement (excluding seniormanagement) and key technicalemployees of the Company

1,220,295 0.50 [REDACTED]

Total 1,688,295 0.62 [REDACTED]

Note:

1. None of the Participants is independent non-executive Director, Supervisor, shareholder that hold morethan 5% of the Company’s shares and the controlling shareholder and their spouses, parents, andchildren.

OTHER INFORMATION

Estate Duty

The Directors have been advised that no material liability for estate duty is likely to fall

on the Group.

Litigation

As of the Latest Practicable Date, the Company was not engaged in any outstanding

litigation or arbitration which may have material adverse effect on the [REDACTED] and, so

far as the Directors are aware, no material litigation or claim was pending or threatened by or

against the Company.

The Joint Sponsors

The Joint Sponsors satisfies the independence criteria applicable to sponsors set out in

Rule 3A.07 of the Listing Rules.

Each of the Joint Sponsors will receive a fee of US$500,000 for acting as the sponsors

for the [REDACTED].


– VI-33 –


Compliance Adviser

The Company has appointed Anglo Chinese Corporate Finance, Limited as the

compliance adviser upon [REDACTED] in compliance with Rules 3A.19 and 19A.05 of the

Listing Rules.

Preliminary Expenses

The Company has not incurred any preliminary expenses.

Promoters

The information of our promoters when we were established as a joint stock limited

company is as follows:

Name of Shareholder

Number ofShares held

upon ourestablishment

Shareholdingpercentage

upon ourestablishment

ALAB 35,308,982 58.848%Dr. Hao Hong 3,738,982 6.232%Hongruntong 2,492,389 4.154%Tianchuang Fuxin 2,482,759 4.138%Guorong Business 2,364,532 3.941%Kunlunjishi 2,068,966 3.448%Shanghe Century 1,891,626 3.153%Ruizhihui 1,730,583 2.884%Chenglun Electric 1,655,172 2.759%Huafang Venture Capital 1,665,172 2.759%Tianchuang Zhongxin 1,241,379 2.069%Junyi Boxing 1,034,483 1.724%Junyi Boying 1,034,483 1.724%Qinghai Mingjiao Co., Ltd. (青海明膠股份有限公司) 827,586 1.379%Aitao Investment 472,906 0.788%

Total 60,000,000 100.00%

Within the two years immediately preceding the date of this document, no cash,

securities, amount or benefit has been paid, allotted or given, or has been proposed to be paid,

allotted or given, to any of the promoters named above in connection with the [REDACTED]

or the related transactions described in this document.


– VI-34 –


Qualifications and Consents of Experts

The qualifications of the experts which have given opinions or advice which are contained

in, or referred to in, this document are as follows:

Name of Expert Qualifications

Goldman Sachs (Asia) L.L.C. A corporation licensed under the SFO to

conduct type 1 (dealing in securities), type 4

(advising on securities), type 5 (advising on

futures contracts), Type 6 (advising on

corporate finance) and type 9 (asset

management) regulated activities

CLSA Capital Markets Limited A corporation licensed under the SFO to

conduct type 4 (advising on securities) and type

6 (advising on corporate finance) regulated

activities

Ernst & Young Certified Public Accountants and

Registered Public Interest Entity Auditor

Deheng PRC legal advisor

Frost & Sullivan (Beijing) Inc.,

Shanghai Branch Co.

Industry consultant

Each of the experts listed above has given and has not withdrawn its written consent to

the issue of this document with the inclusion of its report and/or letter and/or opinion and/or

references to its name included herein in the form and context in which they respectively

appear.

Binding Effect

This document shall have the effect, if an application is made in pursuance hereof, of

rendering all persons concerned bound by all of the provisions (other than the penal provisions)

of Sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions)

Ordinance so far as applicable.

Bilingual document

The English language and Chinese language versions of this document are being

published separately, in reliance upon the exemption provided in Section 4 of the Companies

Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions)

Notice (Chapter 32L of the Laws of Hong Kong).


– VI-35 –


Miscellaneous

(a) Save as disclosed in this section, within the two years preceding the date of this

document, no share or loan capital of the Company or any of its subsidiary has been

issued or has been agreed to be issued fully or partly paid either for cash or for a

consideration other than cash.

(b) No share or loan capital of the Company or any of its subsidiary is under option or

is agreed conditionally or unconditionally to be put under option.

(c) No founder, management or deferred shares of the Company or any of its subsidiary

have been issued or have been agreed to be issued.

(d) Save for our A Shares, none of the equity and debt securities of the Company or its

subsidiary is presently listed or dealt in on any other stock exchange nor is any

listing or permission to deal being or proposed to be sought.

(e) The Company has no outstanding convertible debt securities or debentures.

(f) None of the experts listed under “– Qualifications and Consents of Experts”:

(i) is interested beneficially or non-beneficially in any shares in any member of

the Group; or

(ii) has any right or option (whether legally enforceable or not) to subscribe for or

to nominate persons to subscribe for securities in any member of the Group

save in connection with the [REDACTED].

(g) The English text of this document and the [REDACTED] shall prevail over their

respective Chinese text.

(h) There has not been any interruption in the business of the Group which may have

or has had a significant effect on the financial position of the Group in the 12 months

preceding the date of this document.

(i) The Company currently does not intend to apply for the status of a sino-foreign

investment joint stock limited liability company and does not expect to be subject

to the Law of the PRC on Sino-foreign Equity Joint Ventures.


– VI-36 –


appendix vi statutory and general information

Documents